———. 2012b. 50th anniversary of the Kefauver-Harris Drug Amendments of 1962—interview with FDA historian John Swann. http://www.fda.gov/Drugs/NewsEvents/ucm320927.htm (accessed May 1, 2013).

———. 2012c. Significant dates in U.S. food and drug law history. http://www.fda.gov/aboutfda/whatwedo/history/milestones/ucm128305.htm (accessed November 19, 2012).

———. 2013. International programs: President’s Emergency Plan for AIDS Relief—approved and tentatively approved antiretrovirals in association with the President’s Emergency Plan. http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersForeignOffices/AsiaandAfrica/ucm119231.htm (accessed January 17, 2013).

Fintel, B., A. Samaras, and E. Carias. 2009. The thalidomide tragedy: Lessons for drug safety and regulation. Science in Society. http://scienceinsociety.northwestern.edu/content/articles/2009/research-digest/thalidomide/title-tba (accessed March 5, 2013).

FIP (International Pharmaceutical Federation). 2003. FIP statement of policy on counterfeit medicines. Sydney, Australia.

Flynn, S. 2010. Using competition law to promote access to knowledge. In Access to knowledge in the age of intellectual property. Cambridge, MA: MIT Press.

GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit). 2012. The British Pharmacopoeia (BP). http://www.local-pharma-production.net/index.php?id=148 (accessed January 8, 2013).

Gothoskar, S. S. 1983. Drug control: India. World Development 11(3):223-228.

Government of India. 2003. Report of the Expert Committee on a Comprehensive Examination of Drug Regulatory Issues, Including the Problem of Spurious Drugs. Ministry of Health and Family Welfare, Government of India.

Ho, C. 2011. Global access to medicine: The influence of competing patent perspectives. Fordham International Law Journal 34.

IFPMA (International Federation of Pharmaceutical Manufacturers and Associations). 2010. The IFPMA ten principles on counterfeit medicines. http://www.ifpma.org/fileadmin/content/Global%20Health/Counterfeits/IFPMA_Ten_Principles_Counterfeit_Medicines_12_May_2010.pdf (accessed May 1, 2012).

IMPACT (International Medical Products Anti-Counterfeiting Taskforce). 2008. Summary report. Paper read at Third IMPACT General Meeting, Hammemet, Tunisia.

Indian Pharmacopoeia Commission. 2011. Formation of IPC. http://ipc.nic.in/index2.asp?EncHid=&slid=22&sublinkid=7&lang=1 (accessed November 19, 2012).

IOM (Institute of Medicine). 2012. Ensuring safe foods and medical products through stronger regulatory systems abroad. Washington, DC: The National Academies Press.

Kim, J. H., and A. R. Scialli. 2011. Thalidomide: The tragedy of birth defects and the effective treatment of disease. Toxicological Sciences 122(1):1-6.

Landes, W., and R. Posner. 1987. Trademark law: An economic perspective. Journal of Law and Economics 30(2):265-306.

Mackintosh, M., S. Chaudhuri, and P. Mujinja. 2011. Can NGOs regulate medicines markets? Social enterprise in wholesaling, and access to essential medicines. Globalization and Health 7(1):4.

Mara, K. 2009. Drug seizures in Frankfurt spark fears of EU-wide pattern. Intellectual Property Watch, June 5.

McNeil, D. 2001. Indian company offers to supply AIDS drugs at low cost in Africa. New York Times, February 7.

Miller, J., and G. Anand. 2009. India prepares EU trade complaint. Wall Street Journal, August 6.

Morris, J., and P. Stevens. 2006. Counterfeit medicines in less developed countries: Problems and solutions. London: International Policy Network.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement